Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Maria R. Parkhurst"'
Autor:
Noam Levin, Kristen Hopson, Frank J. Lowery, Mackenzie L. Shindorf, Praveen D. Chatani, Tal Zaks, Maria R. Parkhurst, Stephanie L. Goff, Samantha Seitter, Biman C. Paria, Mohammad S. Jafferji, Jared J. Gartner, Gal Cafri, Rami Yossef, Steven A. Rosenberg, Paul F. Robbins, Todd D. Prickett, Anup Parikh, Christine T. McGowan
Publikováno v:
J Clin Invest
BACKGROUND: Therapeutic vaccinations against cancer have mainly targeted differentiation antigens, cancer-testis antigens, and overexpressed antigens and have thus far resulted in little clinical benefit. Studies conducted by multiple groups have dem
Autor:
Steven A. Rosenberg, Paul F. Robbins, Lien T. Ngo, Rami Yossef, Maria R. Parkhurst, Jared J. Gartner, Li Jia, Mohammad S. Jafferji, Anna Pasetto, Yong-Chen Lu, Abraham Sachs, Todd D. Prickett, Drew C. Deniger, Gal Cafri, Satyajit Ray
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-9 (2019)
Nature Communications
Nature Communications
T cells targeting shared oncogenic mutations can induce durable tumor regression in epithelial cancer patients. Such T cells can be detected in tumor infiltrating lymphocytes, but whether such cells can be detected in the peripheral blood of patients
Autor:
Drew C. Deniger, Sri Krishna, Noam Levin, Sang-hyun Kim, Maria Florentin, Rami Yossef, Maria R. Parkhurst, Anna Pasetto, Lien T. Ngo, Frank J. Lowery, Biman C. Paria, Satyajit Ray, Paul F. Robbins, Steven A. Rosenberg
Publikováno v:
J Immunother
Engineered T cells expressing tumor-specific T cell receptors (TCRs) are emerging as a mode of personalized cancer immunotherapy that requires identification of TCRs against the products of known driver mutations and novel mutations in a timely fashi
Autor:
Todd D. Prickett, Steven A. Rosenberg, Rami Yossef, Gal Cafri, Eric Tran, Anna Pasetto, Paul F. Robbins, Jared J. Gartner, Drew C. Deniger, Maria R. Parkhurst, Alena Gros
Publikováno v:
JCI insight. 3(19)
Adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TILs) targeting neoantigens can mediate tumor regression in selected patients with metastatic epithelial cancer. However, effectively identifying and harnessing neoantigen-reactive T cel
Publikováno v:
Journal of immunotherapy (Hagerstown, Md. : 1997). 39(3)
Wilms tumor gene 1 (WT1) is an attractive target antigen for cancer immunotherapy because it is overexpressed in many hematologic malignancies and solid tumors but has limited, low-level expression in normal adult tissues. Multiple HLA class I and cl
Autor:
John R. Wunderlich, Paul F. Robbins, Alena Gros, Anna Pasetto, Sadia Ilyas, Todd D. Prickett, Eric Tran, James Chih-Hsin Yang, Jessica S. Crystal, Kasia Trebska-Mcgowan, Maria R. Parkhurst, Steven A. Rosenberg, Ilana M. Roberts, Jared J. Gartner
Publikováno v:
Nat Med
Detection of lymphocytes that target tumor-specific mutant neoantigens—derived from products encoded by mutated genes in the tumor—is mostly limited to tumor-resident lymphocytes(1,2), but whether these lymphocytes often occur in the circulation
Autor:
Maria R. Parkhurst, Yong Li, Steven A. Rosenberg, John P. Riley, Mona El-Gamil, Panida Tong-On, Paul F. Robbins
Publikováno v:
The Journal of Immunology. 168:2402-2407
Multiple human cancer Ags have been identified, although little is known concerning which would be most effectively used in cancer immunotherapy. To gain insight into the selection of appropriate Ags, the immunologic reactivity of a patient who had a
Autor:
Steven A. Rosenberg, Simon Turcotte, Maria R. Parkhurst, Paul F. Robbins, John R. Wunderlich, Robert Somerville, Alena Gros, Yong-Chen Lu, Katherine Hogan, Eric Tran, James Chih-Hsin Yang, Mark E. Dudley, Christian S. Hinrichs
Publikováno v:
Science (New York, N.Y.). 344(6184)
T Cells for Epithelial Tumors Malignant tumors harbor genetic alterations. Recently, adoptive T cell therapies have taken advantage of this: T cells specific for mutations in tumors are infused into patients to generate an antitumor immune response.
Autor:
Mark E. Dudley, Udai S. Kammula, Nicholas P. Restifo, Maria R. Parkhurst, Jeremy L. Davis, Maria J. Merino, Ramona M. Lim, Paul F. Robbins, Stephen A. Wank, Steven A. Feldman, Richard A. Morgan, Carolyn M. Laurencot, Giao Q. Phan, Richard M. Sherry, Russell C. Langan, Steven A. Rosenberg, Debbie Ann N. Nathan, Michael S. Hughes, James Chih-Hsin Yang
Publikováno v:
Molecular therapy : the journal of the American Society of Gene Therapy. 19(3)
Autologous T lymphocytes genetically engineered to express a murine T cell receptor (TCR) against human carcinoembryonic antigen (CEA) were administered to three patients with metastatic colorectal cancer refractory to standard treatments. All patien